Gilead
10 Dec 2020
Gilead
NCT02536300
Dose optimization of idelalisib in follicular lymphoma
Gilead Sciences
Cancer Type | Lymphoma |
---|---|
Trial Type | Treatment |
Phase | Phase III |
Age Range | 18 years and older |
Sex | Both |
Tumour Stream | Follicular lymphoma |
Cancer Stage | All stages |
Anticipated Start Date | 2016-01-14 |
Anticipated End Date | 2030-11-01 |
Hospital | Calvary Central Districts Hospital |
---|---|
Clinical Trial Coordinator | Julie Rowe |
julie.rowe@calvarycare.org.au | |
Phone | 08 8239 9536 |
Principal Investigator | Dr Wilfrid Jaksic |
Recruitment Status | Recruiting |